PTC Therapeutics, Inc. (PTCT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $82.00K; Additional Paid in CapitalUSD $2.71B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.02M; Retained Earnings (Accumulated Deficit)USD $-2.88B.
- 2026-03-31: Common Stock, Value, IssuedUSD $81.00K; Additional Paid in CapitalUSD $2.78B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $8.47M; Retained Earnings (Accumulated Deficit)USD $-2.97B.
- 2025-12-31: Common Stock, Value, IssuedUSD $80.00K; Additional Paid in CapitalUSD $2.75B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $10.50M; Retained Earnings (Accumulated Deficit)USD $-2.96B.
- 2025-09-30: Common Stock, Value, IssuedUSD $79.00K; Additional Paid in CapitalUSD $2.67B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.93M; Retained Earnings (Accumulated Deficit)USD $-2.83B.
PTC Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $82.00K | $2.71B | $6.02M | $-2.88B | $-165.36M | 3 month · $23.29M 6 month · $46.71M | (m) | (m) |
| 2026-03-31 | $81.00K | $2.78B | $8.47M | $-2.97B | $-180.47M | 3 month · $23.42M | (m) | (m) |
| 2025-12-31 | $80.00K | $2.75B | $10.50M | $-2.96B | $-205.31M | 12 month · $74.55M | (m) | (m) |
| 2025-09-30 | $79.00K | $2.67B | $5.93M | $-2.83B | $-155.76M | 3 month · $19.43M 9 month · $56.03M | (m) | (m) |
| 2025-06-30 | $78.00K | $2.63B | $7.36M | $-2.85B | $-206.55M | 3 month · $18.54M 6 month · $36.60M | (m) | (m) |
| 2025-03-31 | $78.00K | $2.61B | $-13.95M | $-2.78B | $-185.76M | 3 month · $18.06M | (m) | (m) |
| 2024-12-31 | $77.00K | $2.57B | $-25.89M | $-3.65B | $-1.10B | 12 month · $74.61M | (m) | (m) |
| 2024-09-30 | $76.00K | $2.53B | $-4.34M | $-3.58B | $-1.05B | 3 month · $19.75M 9 month · $57.38M | (m) | (m) |
| 2024-06-30 | $76.00K | $2.51B | $-16.50M | $-3.47B | $-980.18M | 3 month · $19.24M 6 month · $37.62M | (m) | (m) |
| 2024-03-31 | $76.00K | $2.49B | $-5.56M | $-3.38B | $-893.92M | 3 month · $18.38M | (m) | (m) |
| 2023-12-31 | $75.00K | $2.47B | $-1.28M | $-3.28B | $-818.55M | 12 month · $101.64M | (m) | (m) |
| 2023-09-30 | $75.00K | $2.45B | $9.61M | $-3.13B | $-670.81M | 3 month · $26.94M 9 month · $85.13M | (m) | (m) |
| 2023-06-30 | $75.00K | $2.42B | $-1.43M | $-2.99B | $-579.27M | 3 month · $29.37M 6 month · $58.19M | (m) | (m) |
| 2023-03-31 | $73.00K | $2.34B | $-1.59M | $-2.80B | $-457.56M | 3 month · $28.82M | (m) | (m) |
| 2022-12-31 | $72.00K | $2.31B | $4.80M | $-2.66B | $-347.09M | 12 month · $110.33M | (m) | (m) |
| 2022-09-30 | $71.00K | $2.22B | $36.20M | $-2.49B | $-226.90M | 3 month · $28.67M 9 month · $82.99M | (m) | (m) |
| 2022-06-30 | $71.00K | $2.18B | $10.25M | $-2.38B | $-182.22M | 3 month · $27.73M 6 month · $54.32M | (m) | (m) |
| 2022-03-31 | $71.00K | $2.15B | $-18.61M | $-2.22B | $-90.58M | 3 month · $26.59M | (m) | (m) |
| 2021-12-31 | $71.00K | $2.12B | $-24.28M | $-2.10B | $1.44M | 12 month · $103.51M | (m) | (m) |
| 2021-09-30 | $70.00K | $2.09B | $-32.96M | $-1.95B | $104.93M | 3 month · $25.87M 9 month · $77.28M | (m) | (m) |
| 2021-06-30 | $70.00K | $2.06B | $-46.09M | $-1.82B | $196.58M | 3 month · $25.70M 6 month · $51.41M | (m) | (m) |
| 2021-03-31 | $70.00K | $2.03B | $-38.74M | $-1.70B | $292.58M | 3 month · $25.71M | (m) | (m) |
| 2020-12-31 | $70.00K | $2.17B | $-60.96M | $-1.63B | $481.98M | 12 month · $70.33M | (m) | (m) |
| 2020-09-30 | $68.00K | $2.10B | $-35.73M | $-1.55B | $510.95M | 3 month · $16.78M 9 month · $48.91M | (m) | (m) |
| 2020-06-30 | $67.00K | $2.07B | $-10.02M | $-1.48B | $572.49M | 3 month · $16.91M 6 month · $32.13M | (m) | (m) |
| 2020-03-31 | $62.00K | $1.83B | $-1.99M | $-1.30B | $528.73M | 3 month · $15.22M | (m) | (m) |
| 2019-12-31 | $62.00K | $1.80B | $-10.58M | $-1.19B | $594.33M | 12 month · $42.13M | (m) | 12 month · $119.48M |
| 2019-09-30 | $61.00K | $1.78B | $616.00K | $-1.11B | $663.65M | 3 month · $10.48M 9 month · $30.67M | (m) | 3 month · $119.49M 9 month · $119.49M |
| 2019-06-30 | $58.00K | $1.54B | $1.92M | $-1.05B | $488.69M | 3 month · $10.92M 6 month · $20.18M | (m) | (m) |
| 2019-03-31 | $58.00K | $1.52B | $805.00K | $-1.01B | $512.94M | 3 month · $9.26M | (m) | (m) |
| 2018-12-31 | $51.00K | $1.29B | $1.46M | $-938.92M | $350.73M | 12 month · $33.25M | (m) | (m) |
| 2018-09-30 | $51.00K | $1.28B | $1.63M | $-890.59M | $386.09M | 3 month · $8.94M 9 month · $24.77M | (m) | (m) |
| 2018-06-30 | $47.00K | $1.11B | $1.85M | $-839.62M | $267.40M | 3 month · $8.08M 6 month · $15.83M | (m) | (m) |
| 2018-03-31 | $42.00K | $975.42M | $4.95M | $-830.11M | $150.31M | 3 month · $7.75M | (m) | (m) |
| 2017-12-31 | $42.00K | $966.53M | $3.97M | $-814.11M | $156.44M | 12 month · $30.56M | (m) | (m) |
| 2017-09-30 | $41.00K | $958.21M | $3.01M | $-815.38M | $145.88M | (m) | $3.01M | (m) |
| 2017-06-30 | $41.00K | $949.33M | $2.00M | $-781.64M | $169.73M | (m) | $2.00M | (m) |
| 2017-03-31 | $34.00K | $865.83M | $-876.00K | $-764.16M | $100.83M | (m) | $-876.00K | (m) |
| 2016-12-31 | $34.00K | $856.14M | $-1.49M | $-735.11M | $119.58M | 12 month · $35.01M | $-1.49M | (m) |
| 2016-09-30 | $34.00K | $847.70M | $756.00K | $-708.31M | $140.18M | (m) | $756.00K | (m) |
| 2016-06-30 | $34.00K | $837.85M | $885.00K | $-673.14M | $165.62M | (m) | $885.00K | (m) |
| 2016-03-31 | $34.00K | $829.11M | $1.08M | $-634.23M | $196.00M | (m) | (m) | (m) |
| 2015-12-31 | $34.00K | $820.16M | $-1.20M | $-593.00M | $226.00M | 12 month · $33.98M | $-1.20M | 12 month · $55.75M |
| 2015-09-30 | $34.00K | $812.29M | $-1.13M | $-542.05M | $269.15M | (m) | (m) | (m) |
| 2015-06-30 | $34.00K | $747.87M | $-495.00K | $-498.83M | $248.58M | (m) | (m) | (m) |
| 2015-03-31 | $33.00K | $734.49M | $-736.00K | $-460.47M | $273.32M | (m) | (m) | (m) |
| 2014-12-31 | $33.00K | $721.72M | $-737.00K | $-422.55M | $298.47M | 12 month · $19.31M | (m) | (m) |
| 2014-09-30 | $30.00K | $596.62M | $-69.00K | $-395.28M | $201.30M | (m) | (m) | (m) |
| 2014-06-30 | $30.00K | $591.64M | $90.00K | $-368.00M | $223.76M | (m) | (m) | (m) |
| 2014-03-31 | $30.00K | $587.13M | $80.00K | $-342.90M | $244.34M | (m) | (m) | (m) |
| 2013-12-31 | $24.00K | $465.25M | $70.00K | $-328.80M | $136.54M | 12 month · $8.43M | (m) | (m) |
| 2013-09-30 | $24.34K | $461.96M | $-40.47K | $-310.91M | $151.03M | (m) | (m) | (m) |
| 2013-06-30 | $24.34K | $459.39M | $-772.00 | $-306.50M | $152.92M | (m) | (m) | (m) |
| 2012-12-31 | $545.00 | $177.58M | (m) | $-277.22M | $-99.64M | 12 month · $2.29M | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | $-238.60M | 12 month · $2.82M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $3.61K | (m) | $-272.33M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |